Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Lung Cancer, Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/23/2018 |
| Start Date: | July 5, 2017 |
| End Date: | July 2019 |
A Phase II Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
The subjects who take part in this clinical research study have advanced non-small cell lung
cancer (NSCLC) that has been previously treated with other drugs. If they join this study,
they would receive ramucirumab (Cyramza ®) in combination with nab-paclitaxel (Abraxane®).
Ramucirumab given with nab-paclitaxel is considered an investigational drug combination to
use in this type of cancer because giving these two drugs together has not been approved by
any regulatory authority like the US Food and Drug Administration (FDA) for NSCLC cancer.
Ramucirumab works by slowing or stopping the growth of cancer cells. Nab-Paclitaxel works by
blocking the ability of cancer cells to break down the internal 'skeleton' that allows them
to divide and multiply. With the skeleton still in place, the cells cannot divide and they
eventually die.
cancer (NSCLC) that has been previously treated with other drugs. If they join this study,
they would receive ramucirumab (Cyramza ®) in combination with nab-paclitaxel (Abraxane®).
Ramucirumab given with nab-paclitaxel is considered an investigational drug combination to
use in this type of cancer because giving these two drugs together has not been approved by
any regulatory authority like the US Food and Drug Administration (FDA) for NSCLC cancer.
Ramucirumab works by slowing or stopping the growth of cancer cells. Nab-Paclitaxel works by
blocking the ability of cancer cells to break down the internal 'skeleton' that allows them
to divide and multiply. With the skeleton still in place, the cells cannot divide and they
eventually die.
Ramucirumab is a human IgG1 (Immunoglobulin G) monoclonal antibody that targets the
extracellular domain of VEGFR-2 (vascular endothelial growth factor receptor). A recent
double-blind, placebo-controlled clinical trial evaluated the addition of ramucirumab to
docetaxel compared with docetaxel and placebo in patients with Stage IV squamous and
non-squamous NSCLC in the 2nd-line treatment setting. This study demonstrated a superior
overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) with
the combination therapy compared with docetaxel with placebo. This effect was seen across
histologic subtypes, in the absence of excess toxicity in patients with squamous cell
histology. This finding is intriguing, as prior study of bevacizumab in patients with NSCLC
of squamous cell histology was associated with excess pulmonary hemorrhage. This provides the
rationale for further investigation of ramucirumab in patients with squamous cell NSCLC.
nab-Paclitaxel is a formulation of paclitaxel complexed with albumin that is readily soluble
in saline and allows administration of paclitaxel without the use of lipid-based solvents and
the need for corticosteroid and antihistamine premedication. nab-Paclitaxel was approved for
the 1st line treatment of NSCLC based on a trial which demonstrated a superior ORR with the
addition of nab-paclitaxel to carboplatin compared with carboplatin/paclitaxel in patients
with advanced and metastatic NSCLC, as well as prolonged PFS and OS without statistical
significance. The subgroup analysis by tumor histology demonstrated a statistically
significant advantage for nab-paclitaxel/carboplatin in terms of best overall response rate
(41% vs 24%, p<0.001), and numerically better PFS and OS in squamous NSCLC. [3]
This is a single-arm phase II clinical trial, in which patients with previously treated NSCLC
will be treated with ramucirumab/nab-paclitaxel until disease progression, unacceptable
treatment-related toxicity or withdrawal of consent with the primary endpoint of
progression-free survival. A minimum of 40 patients with squamous cell histology will be
required for determination of the co-primary endpoint. The investigators hypothesize that the
addition of ramucirumab to nab-paclitaxel is well-tolerated and associated with a superior
PFS compared with single agent taxane-based therapy.
extracellular domain of VEGFR-2 (vascular endothelial growth factor receptor). A recent
double-blind, placebo-controlled clinical trial evaluated the addition of ramucirumab to
docetaxel compared with docetaxel and placebo in patients with Stage IV squamous and
non-squamous NSCLC in the 2nd-line treatment setting. This study demonstrated a superior
overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) with
the combination therapy compared with docetaxel with placebo. This effect was seen across
histologic subtypes, in the absence of excess toxicity in patients with squamous cell
histology. This finding is intriguing, as prior study of bevacizumab in patients with NSCLC
of squamous cell histology was associated with excess pulmonary hemorrhage. This provides the
rationale for further investigation of ramucirumab in patients with squamous cell NSCLC.
nab-Paclitaxel is a formulation of paclitaxel complexed with albumin that is readily soluble
in saline and allows administration of paclitaxel without the use of lipid-based solvents and
the need for corticosteroid and antihistamine premedication. nab-Paclitaxel was approved for
the 1st line treatment of NSCLC based on a trial which demonstrated a superior ORR with the
addition of nab-paclitaxel to carboplatin compared with carboplatin/paclitaxel in patients
with advanced and metastatic NSCLC, as well as prolonged PFS and OS without statistical
significance. The subgroup analysis by tumor histology demonstrated a statistically
significant advantage for nab-paclitaxel/carboplatin in terms of best overall response rate
(41% vs 24%, p<0.001), and numerically better PFS and OS in squamous NSCLC. [3]
This is a single-arm phase II clinical trial, in which patients with previously treated NSCLC
will be treated with ramucirumab/nab-paclitaxel until disease progression, unacceptable
treatment-related toxicity or withdrawal of consent with the primary endpoint of
progression-free survival. A minimum of 40 patients with squamous cell histology will be
required for determination of the co-primary endpoint. The investigators hypothesize that the
addition of ramucirumab to nab-paclitaxel is well-tolerated and associated with a superior
PFS compared with single agent taxane-based therapy.
Inclusion Criteria:
All patients must have or meet the following:
- Histologically or cytologically confirmed Stage IV (AJCC 7) non-small cell lung
cancer.
- Measurable disease, defined as at least one lesion that can be accurately measured in
at least one dimension as ≥20 mm with conventional techniques or as ≥10 mm with spiral
CT scan, MRI, or calipers by clinical exam.
- Received at least one prior platinum-based chemotherapy for locally advanced or
metastatic disease. Prior bevacizumab as 1st line and/or maintenance therapy is
allowed. Prior nivolumab is allowed.
- Age ≥18 years.
- ECOG performance status ≤2
- Life expectancy of greater than 12 weeks.
- Adequate liver function
- Adequate hematologic function
- Not have cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree)
with a history of hepatic encephalopathy or clinically meaningful ascites resulting
from cirrhosis.
- Adequate renal function
- Urinary protein of ≤1+ on dipstick or routine urinalysis (UA).
- Adequate coagulation function. Patients receiving warfarin must be switched to low
molecular weight heparin and have achieved stable coagulation profile prior to first
dose of protocol therapy.
- Treated and clinically stable brain metastases are allowed.
- Adequate contraceptive use.
- < Grade 2 pre-existing peripheral neuropathy.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
nitrosoureas or mitomycin C) prior to entering the study or those who have not
recovered from adverse events due to agents administered more than 4 weeks earlier.
- Patients with previous intolerance to ramucirumab.
- Patients who are receiving any other investigational agents.
- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to ramucirumab or nab-paclitaxel.
- Patients with untreated CNS metastases.
- Patients with significant bleeding disorders, vasculitis, or who experienced Grade 3/4
gastrointestinal (GI) bleeding within 3 months prior to enrollment.
- History of deep vein thrombosis, pulmonary embolism, or any other significant
thromboembolism during the 3 months prior to enrollment.
- Any arterial thromboembolic events, within 6 months prior to enrollment.
- History of uncontrolled hereditary or acquired thrombotic disorder.
- Uncontrolled or poorly-controlled hypertension.
- A serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to
enrollment.
- Major surgery within 28 days prior to enrollment, or subcutaneous venous access device
placement within 7 days prior to enrollment.
- Chronic antiplatelet therapy, including aspirin, nonsteroidal anti-inflammatory drugs
(NSAIDs, including ibuprofen, naproxen, and others), dipyridamole or clopidogrel, or
similar agents. Once-daily aspirin use (maximum dose 325 mg/day) is permitted.
- Elective or planned major surgery scheduled during the course of the clinical trial.
- Hemoptysis (defined as bright red blood or ≥ 1/2 teaspoon) within 2 months prior to
enrollment, or with central or cavitating lesions.
- Radiologically documented evidence of major blood vessel invasion or encasement by
cancer.
- History of GI perforation and/or fistulae within 6 months prior to enrollment, or risk
factors for perforation.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.
- Pregnancy
- HIV-positive patients on combination antiretroviral therapy.
We found this trial at
1
site
Click here to add this to my saved trials
